3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Motor Activity
1
Lymphoma
1
Leukemia
1
Interventions
pembrolizumab
4
Radiotherapy
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Temozolomide
2
Paclitaxel
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Carboplatin
2
temsirolimus
1
sugemalimab
1
semaglutide
1
sacituzumab govitecan
1
prednylidene
1
pirtobrutinib
1
paricalcitol
1
pamiparib
1
olaparib
1
mirdametinib
1
gadobutrol
1
fludarabine phosphate
1
fludarabine
1
erdafitinib
1
enfortumab vedotin
1
dupilumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
deltacortene
1
daratumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Nadolol
×
30 days
×
Clear all
NCT06643221
2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
200 enrolled